Inpatient management of epidermolysis bullosa: Consensus-based hands-on instructions for neonates and postneonates
- PMID: 38604489
- DOI: 10.1016/j.jaad.2024.04.014
Inpatient management of epidermolysis bullosa: Consensus-based hands-on instructions for neonates and postneonates
Abstract
Background: Epidermolysis bullosa (EB), characterized by skin fragility and blistering, often requires hospitalization. Training for inpatient management of EB is limited, with no unified recommendations available in North America.
Objective: To develop consensus-derived best practices for hands-on inpatient management of EB in both the neonatal and postneonatal period.
Methods: A modified Delphi method (expert-based input via 2 surveys and a final review) was implemented. Available guidelines from EB Clinical Research Consortium centers were analyzed to determine areas of focus and formulate statements to be voted on by EB Clinical Research Consortium members, experienced EB nurses, and select family members. Study participants evaluated statements using a Likert scale: statements with at least 70% agreement were accepted; statements with 30% or more disagreement were rejected.
Results: Ten areas of focus were identified. Delphi participants included 15 dermatologists, 8 nurses, and 6 nonhealth care caregivers. Consensus was established on 103/119 neonatal statements and 105/122 postneonatal statements; no statements were rejected. Most recommendations applied to both age groups.
Limitations: Recommendations may require adjustment based on individual patient's clinical context.
Conclusion: Using the Delphi method, a consensus-derived resource for hospital-based health care professionals who manage patients with EB has been developed to improve the quality of inpatient care.
Keywords: Delphi; epidermolysis bullosa; general dermatology; guidelines; hospital management; medical dermatology.
Copyright © 2024 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest Dr Garcia-Romero has received the EBCRC grant and has been a speaker for Cerave Latinamerica and Carnot Mexico Laboratories. Dr Price’s’ conflicts of interest are Aegle (PI clinical trial), Rheacell (PI clinical trial) Krystal Biotech (consultant). Dr Perman has served as a consultant for Abeona. Dr Lucky has served as investigator for Krystal Pharma and Phoenicis. Dr McCuaig’s conflicts of interest are AbbVie, Bausch, Boehringer, Galderma, Incyte, J&J, Eli Lilly, Leo, Novartis, Oreal Pfizer, Sanofi, and Sun. Dr Gorell has served as a consultant for Krystal Biotech, Abeona Therapeutics, and Amryt Pharma. Dr Levy’s conflicts of interest are Abeona, Castle Creek, Krystal, and Rheacell. Dr Bruckner’s conflicts of interest are Abeona (consultant), Amryt (consultant and investigator), Castle Creek (consultant and investigator), Krystal Biotech (consultant), Phoenix Tissue Repair (investigator), Phoenicis (investigator), Rheacell (investigator), and TWi Bio (consultant). Dr Paller has been an investigator for AbbVie, Applied Pharma Research, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, Regeneron, and UCB; a consultant for Aegerion Pharma, Azitra, BioCryst, Boehringer-Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Johnson & Johnson, Krystal, LEO Pharma, Novartis, Primus, Regeneron, Sanofi/Genzyme, Seanergy, TWI Biotechnology, and UCB; and on the data safety monitoring board for AbbVie, Abeona, Catawba, Galderma, and InMed.
Similar articles
-
Taking care of patients with recessive dystrophic epidermolysis bullosa from birth to adulthood: a multidisciplinary Italian Delphi consensus.Orphanet J Rare Dis. 2025 Mar 16;20(1):128. doi: 10.1186/s13023-025-03635-1. Orphanet J Rare Dis. 2025. PMID: 40091088 Free PMC article.
-
Consensus guidelines for diagnosis and management of anemia in epidermolysis bullosa.Orphanet J Rare Dis. 2023 Feb 23;18(1):38. doi: 10.1186/s13023-022-02448-w. Orphanet J Rare Dis. 2023. PMID: 36823529 Free PMC article. Review.
-
Multicentre consensus recommendations for skin care in inherited epidermolysis bullosa.Orphanet J Rare Dis. 2014 May 20;9:76. doi: 10.1186/1750-1172-9-76. Orphanet J Rare Dis. 2014. PMID: 24884811 Free PMC article. Review.
-
Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool.Pediatr Dermatol. 2015 Jan-Feb;32(1):41-52. doi: 10.1111/pde.12317. Epub 2014 Mar 20. Pediatr Dermatol. 2015. PMID: 24650374
-
A consensus approach to wound care in epidermolysis bullosa.J Am Acad Dermatol. 2012 Nov;67(5):904-17. doi: 10.1016/j.jaad.2012.01.016. Epub 2012 Mar 2. J Am Acad Dermatol. 2012. PMID: 22387035 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources